Revenue and Income - Revenue for the three months ended March 31, 2025, was $324.1 million, an increase of $45.5 million or 16.3% compared to $278.7 million for the same period in 2024[109] - Income from operations for the three months ended March 31, 2025, was $40.4 million, compared to $12.1 million for the same period in 2024[109] - Net income for the three months ended March 31, 2025, was $39.2 million, or 12.1% of revenue, compared to $11.0 million, or 3.9% of revenue in 2024[118] - Total revenue for the three months ended March 31, 2025, was $324.1 million, an increase of 16.3% from $278.7 million in the same period of 2024[123] Product Sales Performance - Global thrombectomy product revenue increased by $38.8 million, or 20.7%, to $226.5 million for the three months ended March 31, 2025[120] - U.S. thrombectomy product sales increased by 25.0% in the three months ended March 31, 2025[120] - Revenue from global embolization and access products increased by $6.6 million, or 7.3%, to $97.6 million for the three months ended March 31, 2025[121] - U.S. embolization and access product sales increased by 16.2% in the three months ended March 31, 2025[121] - Revenue from product sales in international markets decreased by $1.7 million, or 2.5%, to $67.3 million, primarily due to a decline in China revenue[123] Expenses - Research and development expenses for the three months ended March 31, 2025, were $22.1 million, down from $24.6 million in 2024[118] - Sales, general and administrative expenses for the three months ended March 31, 2025, were $153.5 million, compared to $144.4 million in 2024[118] - R&D expenses decreased by $2.5 million, or 10.4%, to $22.1 million, reflecting lower personnel-related costs after exiting the immersive healthcare business[125] - SG&A expenses increased by $9.0 million, or 6.3%, to $153.5 million, primarily due to higher personnel-related expenses and marketing costs[127] Profitability and Margins - Gross profit margin for the three months ended March 31, 2025, was 66.6%, compared to 65.0% for the same period in 2024[118] - Gross margin increased by 1.6 percentage points to 66.6% in Q1 2025, driven by a favorable product mix and productivity improvements[124] - The gross margin for the three months ended March 31, 2025, was positively influenced by a favorable product mix and productivity improvements[154] Cash and Working Capital - As of March 31, 2025, the company had $841.1 million in working capital, including $376.1 million in cash and cash equivalents[132] - Net cash provided by operating activities was $49.0 million, consisting of consolidated net income of $39.2 million and non-cash items of $19.7 million[138] - As of March 31, 2025, the company had cash and cash equivalents of $376.1 million and marketable investments of $2.8 million, primarily in U.S. treasury securities[152] Investment and Financial Policies - The company's investment policy focuses on capital preservation and liquidity needs, investing in highly rated securities while limiting credit exposure to any single issuer[152] - A hypothetical 100 basis point change in interest rates would not materially impact the value of the company's cash and cash equivalents or marketable investments[152] - The company does not enter into derivatives or other financial instruments for trading or speculative purposes, mitigating material market risk exposure[151] Foreign Currency Exposure - The company is exposed to foreign currency risks, billing most sales outside the U.S. in local currencies, primarily euros[153] - An immediate 10% adverse change in foreign exchange rates is not expected to materially impact the company's net income[153] - The company may consider hedging its exposure to foreign currency exchange rate fluctuations in the future[153] Taxation - The provision for income taxes was $3.6 million, or 10.6% of income before taxes, compared to $4.6 million, or 24.8%, in the prior year[130] Other - The company entered into agreements to acquire property in Costa Rica for a new manufacturing facility and warehouse[146] - The remaining authority for share repurchase under the $200 million program is $100 million as of March 31, 2025[134] - There have been no material changes to the company's critical accounting policies from those described in the previous Annual Report[149] - Changes in prices did not significantly impact the company's results of operations for the periods presented in the consolidated financial statements[154]

Revenue Performance - Total revenue for Q1 2025 was $324.1 million, a 16.3% increase from $278.7 million in Q1 2024[4] - Revenue from the United States in Q1 2025 was $256,860,000, a 22.5% increase from $209,644,000 in Q1 2024[28] - U.S. thrombectomy revenue reached $187.9 million in Q1 2025, reflecting a 25.0% increase year-over-year[7] - Thrombectomy product revenue for Q1 2025 was $226,544,000, reflecting a 20.7% increase from $187,703,000 in Q1 2024[29] - The company reported a constant currency revenue growth of 16.9% for the total revenue in Q1 2025[28] Profitability Metrics - Gross profit for Q1 2025 was $215.9 million, representing a gross margin of 66.6%, up from 65.0% in Q1 2024[4] - Income from operations was $40.4 million in Q1 2025, resulting in an operating margin of 12.4%[7] - Net income for Q1 2025 was $39.2 million, with a net income margin of 12.1%[7] - GAAP net income for Q1 2025 was $39,223,000, compared to $11,002,000 in Q1 2024, representing a significant increase[26] - Non-GAAP net income for Q1 2025 was $32,630,000, up from $16,182,000 in Q1 2024, reflecting a growth of 101.5%[26] - The GAAP net income margin improved to 12.1% in Q1 2025 from 3.9% in Q1 2024[27] Expenses and Cost Management - Operating expenses for Q1 2025 totaled $175.5 million, or 54.2% of total revenue, down from 60.7% in Q1 2024[5] - Research and development expenses were $22.1 million in Q1 2025, down from $24.6 million in Q1 2024[5] - Non-recurring litigation related expenses were $0 in Q1 2025, compared to $4,823,000 in Q1 2024[26] Future Projections - The company projects total revenue for 2025 to be between $1,340 million and $1,360 million[6] - Guidance for U.S. thrombectomy franchise growth has been increased to 20% to 21% year-over-year[6] EBITDA Performance - Adjusted EBITDA for Q1 2025 was $59.6 million, resulting in an adjusted EBITDA margin of 18.4%[7] - Adjusted EBITDA for Q1 2025 was $59,595,000, compared to $37,646,000 in Q1 2024, indicating a growth of 58.3%[27] Earnings Per Share - GAAP diluted EPS for Q1 2025 was $1.00, up from $0.28 in Q1 2024[26]

Core Insights - Penumbra, Inc. reported a total revenue of $324.1 million for Q1 2025, marking a 16.3% increase compared to $278.7 million in Q1 2024, with a 16.9% increase in constant currency [2][11][25] - The U.S. market accounted for 79.2% of total revenue, with U.S. thrombectomy revenue increasing by 25.0% year-over-year [2][11][27] - The company anticipates total revenue for 2025 to be between $1,340 million and $1,360 million, with U.S. thrombectomy growth guidance raised to 20%-21% [7][11] Financial Performance - Gross profit for Q1 2025 was $215.9 million, representing a gross margin of 66.6%, up from 65.0% in Q1 2024, driven by a favorable product mix and productivity improvements [3][19] - Total operating expenses were $175.5 million, or 54.2% of total revenue, down from 60.7% in Q1 2024, excluding non-recurring litigation expenses [4][19] - Income from operations for Q1 2025 was $40.4 million, compared to $12.1 million in Q1 2024, indicating a significant operational improvement [5][19] Product Performance - Revenue from global thrombectomy products reached $226.5 million, a 20.7% increase year-over-year, primarily due to U.S. sales growth [2][26] - Revenue from global embolization and access products grew to $97.6 million, a 7.3% increase, with U.S. sales increasing by 16.2% [2][26][27] Market Outlook - The company expects gross margin to expand by at least 100 basis points in 2025, targeting over 67% for the full year [7] - Operating margin is projected to expand to a range of 13% to 14% of revenue for the full year 2025 [7]

Core Viewpoint - Kaskela Law LLC is investigating Penumbra, Inc. on behalf of its current shareholders to determine potential violations of securities laws or breaches of fiduciary duties by the company and its officers [1][2]. Group 1 - The investigation is focused on recent corporate actions taken by Penumbra that may have affected shareholder interests [2]. - Shareholders are encouraged to reach out to Kaskela Law LLC for more information regarding their legal rights and options [3]. Group 2 - Kaskela Law LLC specializes in representing investors in cases related to securities fraud, corporate governance, and merger & acquisition litigation [3]. - The firm operates on a contingent basis, meaning they only get paid if the case is successful [3].

Core Viewpoint - Penumbra (PEN) is well-positioned to continue its earnings-beat streak, having surpassed earnings estimates consistently in recent quarters [1][5]. Earnings Performance - In the most recent quarter, Penumbra reported earnings of $0.97 per share, exceeding the expected $0.91 per share by 6.59% [2]. - For the previous quarter, the company reported $0.85 per share against an expectation of $0.69 per share, resulting in a surprise of 23.19% [2]. Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Penumbra, with a positive Earnings ESP of +1.97%, indicating bullish sentiment among analysts regarding the company's earnings prospects [5][8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that such combinations lead to positive surprises nearly 70% of the time [6][8]. Upcoming Earnings Report - The next earnings report for Penumbra is expected to be released on April 23, 2025 [8].

Penumbra, Inc.’s (PEN) thrombectomy business is thriving, driven by growing sales of the U.S. vascular thrombectomy and CAVT (computer-assisted vacuum thrombectomy) line of products. The company’s robust product portfolio expansion is poised to drive growth in the upcoming quarters. Meanwhile, unfavorable foreign exchange and intense competition may pose operational risks for PEN.               In the past year, shares of this Zacks Rank #2 (Buy) company have increased 19.8% against the industry’s 18.4% dec ...

NEW YORK, April 8, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Penumbra, Inc. (NYSE: PEN) on behalf of the company's shareholders.  The investigation seeks to determine whether Penumbra's directors breached their fiduciary duties in connection with recent corporate actions.If you are a shareholder of Penumbra and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: https://pjlfirm.com/penumbra-inc/You ma ...

ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the web ...

ALAMEDA, Calif., April 2, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy for blood clots not only improved clinical and functional outcomes but can also help reduce overall healthcare costs.  Seven New Data Sets Demonstrate Penumbra’s Co ...

Core Viewpoint - Penumbra is experiencing strong growth in its thrombectomy business, particularly in the U.S. market, but faces challenges from unfavorable currency movements and rising expenses [1][2][7]. Group 1: Business Performance - Penumbra's thrombectomy business is showing robust growth, with a 27.3% year-over-year increase in the U.S. for Q4 2024, driven by the adoption of its CAVT portfolio and new products [2]. - The U.S. VTE franchise reported a revenue growth of 41% year-over-year [2]. - Over the past three months, Penumbra's shares have increased by 16.7%, outperforming the industry, which saw a 5.6% decline [6]. Group 2: Product Launches and Innovations - The Element Vascular Access System was launched in January 2025, designed for venous thromboembolism treatments and compatible with the Lightning Flash 2.0 system [3]. - New products, including Lightning Bolt 12 and Lightning Bolt 6x with TraX, were launched in 2025 to enhance thrombus management [4]. - The company plans to focus on innovations within its Flash and Bolt product lines [4]. Group 3: International Market and Revenue - Approximately 24.5% of Penumbra's revenue in 2025 is expected to come from international markets, with plans to increase revenues and profitability in these regions [5]. - The company aims to introduce its advanced products, including RED catheters and Lightning series, to global teams [5]. Group 4: Cost and Expense Challenges - Penumbra's sales and costs are significantly affected by foreign exchange rate fluctuations, with 29% of consolidated revenues coming from non-U.S. markets in 2024 [7]. - The company faced a 7.3% increase in the cost of revenues and a 13.8% rise in selling, general, and administrative expenses year-over-year in Q4 2024 [8].